Peer Review History

Original SubmissionFebruary 22, 2022
Decision Letter - Amita Radhakrishnan Nair, Editor

PONE-D-22-03454Reducing the risk of transfusion-transmitted infectious disease markers in blood and blood component donations: movement from remunerated to voluntary, non-remunerated donations in Lithuania from 2013 to 2020PLOS ONE

Dear Dr. Kalibatas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 28 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Amita Radhakrishnan Nair

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Additional Editor Comments:

Dear Author,

The work you have done is very good.

But I have certain reservations.

Serological test always carries an element of false positivity. Was any other test done to confirm the positive status of donor?

All repetitions may be deleted.

The results sections has to be re-written and concise

1. Line 31, Please rewrite as HIV 1 and 2.

2. Line 207-215, If for statistical analysis, sample size is insufficient, need not look at the statistics.

3. Year wise statistics has not much relevance. It can be combined together

4. Line 205-208, where sufficient numbers not available, tests of significance carries no value. Such results may be omitted

5. Line 232- not complete

6. Were the TTI reactive donors contact and post test counselling done to assess the risk behaviors?

7. Line 297-98, what could be the reason for this finding?

8. Help of a statistician may be sought for better presentation of the results.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor,

We thank you and the reviewers for a thorough reading and constructive criticism of our manuscript and for the opportunity to revise and resubmit. We are pleased to submit the improved research article “Reducing the risk of transfusion-transmitted infectious disease markers in blood and blood component donations: movement from remunerated to voluntary, non-remunerated donations in Lithuania from 2013 to 2020” for your consideration for publication in PLOS ONE. On the following pages, you will find our response to the Editor comments.

On behalf of the authors, I thank you for your consideration of this resubmission. We appreciate your time and look forward to your response.

Sincerely,

Ass. Prof. Vytenis Kalibatas, MD, MPH, PhD (corresponding author)

Department of Health Management,

Lithuanian University of Health Sciences

Tilžės str. 18, LT-47181, Kaunas, Lithuania

E-mail: vytenis.kalibatas@lsmuni.lt

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We thank you for the advices on the revision. We followed the templates and changed the figure file according to the requirements.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

We have uploaded our supplementary information in S1 Table. All relevant data are within the article and its supporting information.

Additional Editor Comments:

1. Serological test always carries an element of false positivity. Was any other test done to confirm the positive status of donor?

In the manuscript, we have used the word "confirmed", which we treated as "a priori" explanation that we provide the data only on confirmed TTI markers, not initially positive.

Anyway, to make the text more understandable for all readers, we added some explanations regarding the confirmatory testing in the "Material and methods" section (125-134

lines in Manuscript; 125-133 lines in the Revised Manuscript with Track Changes).

2. All repetitions may be deleted.

We have removed all repetitions in the "Results" section and included the additional table in the Supporting Information.

3. The results sections has to be re-written and concise.

We rewrote the "Results" section and concise the text.

4. Line 31, Please rewrite as HIV 1 and 2.

We corrected the marker in the “Abstract” section.

5. Line 207-215, If for statistical analysis, sample size is insufficient, need not look at the statistics.

We deleted sentences in lines 207-215, and added that due to insufficient sample sizes comparisons with VNRDs are not applicable (lines 179-180 in Manuscript; lines 208-209 in

the Revised Manuscript with Track Changes).

6. Year wise statistics has not much relevance. It can be combined together.

Thank you for this comment. We could agree with it if we emphasize a sufficient sample size of remunerated donations in some years. By combining some years (for example,

2013-2014; 2015- 2016, etc.), we miss some important aspects of showing the breaking points from prevailing remunerated to VNRDs, and the shift towards the safest donation

group - repeat VNRDs, which prevails starting from 2016. On the other hand, combining two or more years does not solve the problem of a sufficient sample size for first-time

remunerated donations. In a manuscript, we provide the pooled data, combining all years, but we also think that data presented yearly give some useful information about

donations' changes.

7. Line 205-208, where sufficient numbers not available, tests of significance carries no value. Such results may be omitted.

We deleted sentences in lines 205-205, and added that due to insufficient sample sizes comparisons with VNRDs are not applicable (lines 179-180 in Manuscript; lines 208-209 in

the Revised Manuscript with Track Changes).

8. Line 232- not complete.

We added the year 2020 (line 209 in Manuscript; line 233 in the Revised Manuscript with Track Changes).

9. Were the TTI reactive donors contact and post test counselling done to assess the risk behaviors?

In answering the question, we provided the additional information in the “Discussion” section (lines 319-325 in Manuscript; lines 394 - 400 in the Revised Manuscript with Track

Changes).

10. Line 297-98, what could be the reason for this finding?

Thank you for pointing it out. The sentence was incorrect: “repeat VNRDs are safer than repeat non-remunerated donations”. We corrected the sentence (lines 272-273 in

Manuscript; lines 346 - 347 in the Revised Manuscript with Track Changes).

11. Help of a statistician may be sought for better presentation of the results.

We consulted with a statistician and made some changes in calculations (z-test instead of chi-square test for comparisons of prevalence), as well as in the interpretation of the

results.

Attachments
Attachment
Submitted filename: Response to Reviewer.docx
Decision Letter - Mohamed A Yassin, Editor

Reducing the risk of transfusion-transmitted infectious disease markers in blood and blood component donations: movement from remunerated to voluntary, non-remunerated donations in Lithuania from 2013 to 2020

PONE-D-22-03454R1

Dear Dr.Kalibatas ,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mohamed A Yassin, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear authors in this manuscript you described about the role of voluntary non-renumerated donation in reducing the risk of transfusion transmitted infectious diseases. You responded previous reviewer’s comments very nicely, but there are minor changes can improve the manuscript.

Specific comments:

1. In this manuscript you used the term for HIV used in various different words such as somewhere you used “HIV” only while in soe places you used “HIV 1 and 2”, it would be great if you use the same term “HIV 1 and 2” in whole manuscript.

2. In introduction section line 53-60, the donor was paid for donations (12 euro from year 2015), is this practice is still in place.

3. In material and method line 125, you mentioned that blood donation was tested for serological markers for various TTIs. It would be great if you could mention the method for serological testing such as rapid test or ELISA or Chemiluminescence test.

4. You mentioned Fig 1 and Table 1 I material and method section, I feel that it should be included under result section because these are your findings of the study about annual blood donation.

5. In this manuscript you did not mention about co-infections, kindly mention if there were any co-infections (like donor was reactive for two or more TTIs).

6. In discussion line 237 you mentioned the payment 11.6 euro per donation from 2013 to 2020, while in introduction section line 53-60 you mentioned that payment increased to 12 euro from year 2015. These both are quite confusing statements. Kindly clarify.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Mohamed A Yassin, Editor

PONE-D-22-03454R1

Reducing the risk of transfusion-transmitted infectious disease markers in blood and blood component donations: movement from remunerated to voluntary, non-remunerated donations in Lithuania from 2013 to 2020

Dear Dr. Kalibatas:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mohamed A Yassin

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .